The FDA approved Dupixent (dupilumab) as a treatment for moderate-to-severe atopic dermatitis for adolescents in 2019, then for older children, ages 6 to 11, a year later, and, two years later, for ...

Cardiovascular disease (CVD) became the leading cause of death in Hispanic adults in the U.S. in 2022, ahead of cancer, and researchers have been taking a closer look into this population of roughly ...

A five-session course of transcranial magnetic stimulation (TMS) improved processing speed in people with schizophrenia, a cognitive domain that is among the most severely affected in patients, Five ...

OrionRx's Don Anderson, Pharm.D., says a GLP-1 access model built around mandatory wellness coaching resulted in a six-point ...

National Alliance of Healthcare Purchaser Coalitions (National Alliance) has named Jenny Goins its interim president and CEO ...

Kessler, a principal at Milliman, says employers need to pay attention to their claims and pharmacy benefit contracts.

As PBMs plan for 2028 rollout of the PBM transparency provisions of the Consolidated Appropriations Act of 2026 (CAA 2026) ...

GLP-1 therapies continue to materially influence drug spend, with 2025 overall trend at 8.4% versus 7.9% excluding GLP-1s, ...

Optum Rx's automated prior authorization tool, PreCheck Prior Authorization, is automating almost two-thirds of approved ...

FDA expands accelerated approval of oral sevabertinib for first-line HER2-mutant lung cancer, offering targeted treatment with strong response rates versus standard chemotherapy.

Judi Health and the group purchasing organization Employers Health have teamed up to launch StarkRx, a modular, cost-plus pharmacy benefit solution. Judi Health’s PBM, Judi Rx, will provide the ...

Cognitive agency over music choice aligned with lower pain and greater tolerance, paralleling findings in advanced cancer ...